News - Onglyza, Bristol-Myers Squibb

Filter

Popular Filters

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

Bristol-Myers Squibb releases strong third quarter results

Bristol-Myers Squibb releases strong third quarter results

23-10-2013

Bristol-Myers Squibb has announced strong third quarter results with sales up 9% to $4.1 billion.

BaracludeBristol-Myers SquibbFinancialNorth AmericaOnglyzaOrenciaPharmaceuticalSprycelYervoy

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

27-09-2013

Bristol-Myers Squibb and partner AstraZeneca have announced additional results from the SAVOR cardiovascular…

AstraZenecaBristol-Myers SquibbDiabetesOnglyzaPharmaceuticalResearch

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs

26-07-2013

Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib

14-05-2013

Under the rules of the German Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute…

AstraZenecaBristol-Myers SquibbcrizotinibDiabetesEuropeKomboglyzeOncologyOnglyzaPfizerPharmaceuticalPricingRegulationsaxagliptinXalkori

EC approves additional use for Bristol-Myers and AstraZeneca’s Onglyza and Komboglyze

29-11-2011

The European Commission has approved drug majors Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca’s…

AstraZenecaBristol-Myers SquibbDiabetesEuropeKomboglyzeOnglyzaPharmaceuticalResearch

Back to top